Squamous cell carcinoma (SCC) of the anal canal is a relatively rare malignancy, but its incidence has increased over the last few years.[@CR1] Currently, chemoradiotherapy (CRT) is standard of care for anal cancer, resulting in superior local control compared with radiotherapy alone with 5-year survival rates of 60--80%.[@CR2]--[@CR8] CRT leads to preservation of the anal sphincter by avoiding surgery. Unfortunately, CRT fails in 20--30% of patients, resulting in persistent (10--15%) or local recurrent disease (10--15%).[@CR2]--[@CR7],[@CR9]

Salvage abdominoperineal resection (APR) is often the only option for patients with persistent or recurrent anal SCC to achieve durable local control and survival. Several institutes have reported case series on this topic. However, due to heterogeneity in treatment protocols, results on patient outcomes vary widely.[@CR10]--[@CR20] Our institute has a well-established protocol for treatment of anal SCC, which has changed little in the last three decades. The aims of the present study are to analyze the results of a 30-year experience with salvage APR for recurrent and persistent anal SCC after failed CRT in a large single-center cohort and to identify prognostic factors for overall survival. In addition, outcomes of patients treated for local recurrence developed after primary salvage APR for persistent or recurrent SCC were also analyzed. To the best of the authors' knowledge, results of repeat surgery for treatment of local recurrence after salvage APR have never been previously studied.

PATIENTS AND METHODS {#Sec2}
====================

Data of all consecutive patients who underwent salvage APR with curative intent for histologically confirmed persistent or recurrent anal SCC between 1990 and 2016 at the Erasmus MC Cancer Institute, a tertiary referral center in The Netherlands, were retrospectively analyzed. Patient demographics, perioperative variables, tumor characteristics, neoadjuvant therapy, short- and long-term outcomes, and postoperative mortality and morbidity were collected from medical records, the municipality register, and general practitioners. All patients were followed up by our institute; last update of follow-up was 22 January 2018. The present study was approved by the Erasmus MC local medical ethics committee (registration number MEC-2017-448).

Primary Treatment {#Sec3}
-----------------

All primary malignancies were initially treated with radiotherapy, and the majority (78.7%) also received concomitant chemotherapy. Radiotherapy was administered with median dose of 60 Gy \[interquartile range (IQR) 60--60 Gy\], and chemotherapy was administered in the first four days of the first week \[5-fluorouracil (1000 mg/m^2^) and mitomycin C (10 mg/m^2^)\]. Patients with histologically proven anal SCC within 6 months after the last day of radiotherapy, or patients with incomplete response, were classified as having persistent disease. Initial complete responders to (chemo)radiotherapy, who were diagnosed with biopsy-proven recurrent anal SCC, after 6 months or more since the last day of radiotherapy, were classified as having recurrent disease.

Staging {#Sec4}
-------

Tumor stage was assessed by physical examination and radiologic imaging according to the American Joint Committee on Cancer (AJCC) tumor--node--metastasis (TNM) staging system (7th edition) for cancer of the anal canal. Nodal stage was assessed by pelvic magnetic resonance imaging (MRI), and suspicious inguinal lymph nodes were biopsied. Computed tomography (CT) scans of the chest and abdomen were used to confirm absence of metastatic disease prior to surgery.

Surgery {#Sec5}
-------

All patients deemed eligible for complete, curative resection underwent salvage APR. Multivisceral resection was performed if necessary. If possible, omentoplasty was performed to fill the pelvis. Primary closure of the perineal defect was routinely performed up to 1999, and if this was not feasible, the open wound was packed for healing by secondary intention. From 2000 onwards, the perineal defect was reconstructed with either a vertical rectus abdominis myocutaneous (VRAM) or gracilis muscle flap.[@CR21],[@CR22] Inguinal lymph node dissection was performed in case of biopsy-proven positive lymph nodes. Postoperative complications were graded according to the Dindo--Clavien classification.[@CR23] Local recurrence after salvage APR was defined as any local recurrence after salvage APR, regardless of whether the indication for salvage APR was for persistent or recurrent anal SCC.

Statistics {#Sec6}
----------

Survival analysis was performed by Kaplan--Meier method, and comparisons were made using log-rank tests. Survival was calculated from day of APR until data of death or last follow-up. Survival rates for recurrence after salvage APR were calculated from date of diagnosis of recurrent anal SCC until death or last follow-up. Cox proportional-hazard models were constructed to identify prognostic factors in univariable and multivariable analysis. Mann--Whitney *U* and chi-squared test were performed as appropriate. Covariables with a trend towards significance (*p* \< 0.100) were selected for multivariable analysis, with a maximum of three considering the number of events. Two-sided *p*-values \< 0.05 were considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics version 24.0.0 for Windows (IBM Corp, Armonk, New York, USA).

RESULTS {#Sec7}
=======

Forty-seven consecutive patients underwent salvage APR for anal SCC between 1990 and 2016. Patient characteristics are depicted in Table [1](#Tab1){ref-type="table"}.Table 1Patient and tumor characteristics before and after abdominoperineal resection (*N* = 47)*N*%Gender Male2757.4 Female2042.6Age At time of diagnosis primary53 (46--66)\* At time of operation56 (48--66)\*Clinical tumor stage T18 17.0 T22042.6 T31327.7 T4612.8Clinical nodal stage N0/Nx4085.1 N1510.6 N224.3Clinical Metastasis stage M04595.7 M+24.3Histology Squamous cell carcinoma47100Pretreatment Radiotherapy47100 Mean dose Gy60 (60--60)\*Concomitant chemotherapy 5-FU Mitomycin C3676.6 5-FU only12.1 No chemotherapy1021.3Indication for surgery Persistent disease2448.9 Recurrent disease2351.1Time interval radiotherapy and surgery (in months) Persistent disease5 (4--7)\* Recurrent disease15.0 (9.5--37.5)\*Surgical procedure APR3574.5 APR and posterior vaginal wall48.5 Posterior exenteration48.5 Total pelvic exenteration24.3 Posterior exenteration and vulvectomie244.3Additional procedures Partial sacrectomy24.3 Synchronous ILND24.3 Omentoplasty3370.2 IORT24.3Wound closure and/or reconstruction Primary closure1021.3 Wound left open12.1 VRAM-flap3166.0 Gracilis flap36.4 Pudendus flap12.1 Gluteal flap12.1Operating time Minutes378.6 ± 129.9\*\*Pathological tumor size Maximum diameter (millimeter)30.0 (20.0--48.3)\*Pathological nodal stage N0/Nx4187.2 N124.3 N248.5Pathological metastases stage M0/Mx4391.5 M148.5Vasoinvasion Yes1123.3 No1838.3 Unknown1838.3Perineural growth Yes1429.8 No1531.3 Unknown1838.3Pathological resection margins R03880.9 R1817.0 R212.1\*Median and interquartile range, \*\*Mean and standard deviation*APR* abdominoperineal resection, *IORT* intra-operative radiotherapy, *VRAM* vertical rectus abdominus muscle, *ILND* Inguinal lymph node dissection, *5-FU* 5-fluorouracil

Surgical Results {#Sec8}
----------------

Indications for surgery were either persistent (*n* = 24; 48.9%) or recurrent disease (*n* = 23; 51.1%). Median time between the last day of (chemo)radiotherapy and date of surgery was 5 months (IQR 4--7 months) for patients with persistent disease and 15 months (IQR 9.5--37.5 months) for patients with recurrent disease. APR without additional resections was performed in 35 patients, APR with posterior vaginal wall resection in 4 patients, posterior exenteration in 6 patients (including vulvectomy in 2 patients), and total pelvic exenteration in 2 patients. Other additional procedures were partial sacrectomy (*n* = 2), synchronous inguinal lymph node dissection (*n* = 2), and intraoperative radiotherapy (IORT, *n* = 2). Omentoplasty was performed in 33 patients. One patient had two lesions in the liver suspicious for metastases, which were histopathologically confirmed by frozen section. Salvage APR was performed, but the liver metastases were not resected. Until 1999, primary perineal closure was performed in seven patients, one open wound was packed for secondary healing, and one gluteal transposition flap was performed for reconstruction. In 38 patients treated from 2000 onwards, primary perineal closure was performed three times, while a locoregional flap for perineal closure was used 35 times \[VRAM flap (*n* = 31), gracilis muscle flap (*n* = 3), and bilateral pudendal flap (*n* = 1)\]. Surgical characteristics are presented in Table [1](#Tab1){ref-type="table"}. Radical resection (R0) was achieved in 38 patients (80.9%), microscopically irradical resection (R1) in 8 patients (17.0%), and macroscopically irradical resection (R2) in 1 patient (2.1%). One patient had liver metastases, and three patients had inguinal lymph node metastases. Tumor characteristics are listed in Table [1](#Tab1){ref-type="table"}.

Mortality and Morbidity {#Sec9}
-----------------------

None of the patients died within 30 days of surgery. Within 2 months, there was one case of euthanasia due to unbearable suffering from severe wound infection and no perspective of cure considering confirmed liver metastases. The majority of patients (*n* = 33; 70.3%) experienced no or minor complications (Dindo--Clavien ≤ 2), and 14 patients (29.7%) developed major complications (Dindo--Clavien ≥ 3). Mortality and morbidity are displayed in Table [2](#Tab2){ref-type="table"}. Six out of 10 patients with primary closure of the perineal defect and 9 out of 36 patients with muscle flap reconstruction (MFR) experienced perineal wound complications. Nine patients required surgery for perineal wound complications. The latter were treated with debridement with (*n* = 5) or without vacuum-assisted closure therapy (*n* = 2) and muscle flap necrosectomy followed by repeat reconstruction (*n* = 2). Median time between last day of radiotherapy and surgery did not significantly influence perineal wound complications (*p* = 0.909). The proportion of patients with perineal wound complications was lower in patients treated with MFR (25%; 9/36) compared with patients treated without MFR (54.5%; 6/11), however this was not significant (*p* = 0.066).Table 2Mortality, morbidity, and perineal wound complications*N*%Mortality \< 30 days after surgery00 During hospital admission12.1Dindo-Clavien None1736.2 Dindo 1612.8 Dindo 21021.3 Dindo 3A12.1 Dindo 3B1021.3 Dindo 436.4 Dindo 500Major complications Pulmonary embolism12.1 Aspiration pneumonia24 Gastric ulcer bleeding12.1Major complications requiring surgery Stoma necrosis12.1 Abdominal wound necrosis12.1 Fascia dehiscence12.1Perineal wound complicationsMFR (*N* = 36)No MFR (*N* = 11)Additional muscle flap reconstruction11Vacuum assisted therapy32Wound complication treated conservative43Wound complication requiring debridement20Perineal hernia11*MFR* muscle flap reconstruction

Survival {#Sec10}
--------

Median follow-up time was 80 months (95% CI 68.6--91.4 months). At last follow-up, 19 patients (40.4%) were alive. Median overall survival (OS) was 47 months (95% CI 10.0--84.0 months), and the estimated 5-year survival rate was 41.6%. Survival curves did not differ significantly between patients with persistent versus recurrent disease (5-year survival rate 40.4 vs. 41.7%, respectively; *p* = 0.551). Survival curves are shown in Fig. [1](#Fig1){ref-type="fig"}. On both univariable and multivariable analysis, increased pathological tumor size (*p* \< 0.001) and positive lymph nodes (*p* = 0.014) were significantly associated with worse OS. Irradical resection was only significantly associated on univariable analysis (*p* = 0.001) but not on multivariable analysis (*p* = 0.087). Analyses are presented in Table [3](#Tab3){ref-type="table"}, and the influence on survival in Fig. [2](#Fig2){ref-type="fig"}.Table 3Univariable and multivariable survival analysis for overall survival of squamous cell carcinomaUnivariable*P* valueMultivariable*P* valueHazard ratio \[95% CI\]Hazard ratio \[95% CI\]Male versus female1.150 \[0.536--2.466\]0.720----Age at time of operation1.021 \[0.986--1.058\]0.239----CTxRTx versus RTx0.884 \[0.332--2.351\]0.805----Recurrent disease versus persistent disease0.794 \[0.794--1.709\]0.556----Multivisceral resection1.169 \[0.524--2.608\]0.704----Irradical resection (R1/R2)4.056 \[1.746--9.423\]0.0012.786 \[0.862--9.005\]0.087Node positive (N1/N2)3.228 \[1.255--8.302\]0.0154.445 \[1.356--14.563\]0.014Metastasis positive (M1)2.603 \[0.878--7.712\]0.084----Vasoinvasion2.081 \[0.795--5.679\]0.144----Perineural growth2.702 \[0.973--7.504\]0.056----Pathological tumor size (maximum diameter in mm)1.039 \[1.023--1.055\]\< 0.0011.036 \[1.018--1.054\]\< 0.001*CTxRTx* chemoradiotherapy, *RTx* radiotherapyFig. 1**a** Overall survival (OS). **b** Local recurrence-free survival (LRFS). **c** OS for persistent versus recurrent disease. **d** OS for local recurrence after salvage APR; repeat salvage surgery versus palliative treatment Fig. 2Overall survival curves (prognostic factors): **a** resection margin, **b** nodal stage, and **c** pathological tumor size (diameter in millimeters with median as cutoff value)

Recurrence after Salvage APR {#Sec11}
----------------------------

The overall rate of disease recurrence after salvage APR was 55.3%. Twenty-one patients (44.7%) developed local recurrence after salvage APR, including 13 patients with simultaneous locoregional recurrence or distant metastases \[inguinal lymph node (*n* = 7), liver (*n* = 2), adrenal gland (*n* = 1), retroperitoneal lymph nodes (*n* = 1), peritoneal carcinomatosis (*n* = 1), and cervical lymph node + liver metastasis (*n* = 1)\]. Five patients developed distant metastases or locoregional recurrence only \[inguinal lymph node (*n* = 2), retroperitoneal lymph nodes (*n* = 1), hilar lymph nodes (*n* = 1), liver metastases (*n* = 1)\]. Median OS for patients with local recurrence and/or distant metastases after salvage APR was 12 months (95% CI 8.3--15.7 months). Median local-recurrence-free survival after salvage APR (LRFS) was not reached. The estimated 5-year LRFS after salvage APR was 51.1%. None of the patients developed local recurrence after 42 months from salvage APR. Three patients received postoperative chemotherapy for metastatic disease, and none of the patients received standard adjuvant chemotherapy.

Eight patients with local recurrence after salvage APR underwent repeat salvage surgery by extensive local excision, including additional inguinal lymph node dissection (*n* = 2), liver metastases resection (*n* = 1), and cervical lymph node dissection (*n* = 1).

Thirteen patients underwent palliative treatment for local recurrence after salvage APR, including fistula resection (*n* = 2), radiotherapy in combination with hyperthermia (*n* = 2), and chemotherapy for metastatic disease (*n* = 2), while seven patients received best supportive care only. Median OS for all patients with local recurrence after salvage APR, calculated from date of diagnosis of local recurrence, was 7 months (95% CI 1.0--13.0 months). The 1-year survival rate was 19.0%, and all patients died within 15 months except for one patient, who had undergone repeat salvage surgery and was still alive at last follow-up of 22 months.

There was no significant difference (*p* = 0.055) in survival of patients with local recurrence after salvage APR treated with repeat salvage surgery, with median OS of 9 months (95% CI 7.2--10.8 months), compared with patients with palliative treatment, with median OS of 4 months (95% CI 2.8--5.1 months).

DISCUSSION {#Sec12}
==========

The present study describes the results of salvage APR for SCC of the anal canal after failure of initial primary therapy in 47 patients. Overall estimated 5-year survival was 41.6%. Negative prognostic factors were increased pathological tumor size and lymph node involvement on multivariable analysis, and positive resection margin only on univariable analysis. Type of local failure did not affect survival. The overall local recurrence rate after salvage APR was 44.7%. None of the patients who developed local recurrence after salvage APR could be cured, and all had poor prognosis.

Although surgery has been replaced by CRT for primary treatment of SCC of the anal canal, salvage APR has remained the gold standard for patients with persistent disease or local recurrent disease after failed CRT. Due to the relative rarity of the procedure for this indication, most published series consist of only a small number of patients treated over a long period of time, and are therefore prone to a certain degree of bias. We present herein a rather homogeneous group of patients. All patients were treated with an adequate radiation dose of \> 45 Gy, and all but eight patients received the standard protocol of 60 Gy. This in contrast to some other published series where the study population was treated with a wide range of radiation doses.[@CR9]--[@CR11],[@CR16]

The percentages of radical resection and 30-day postoperative mortality are comparable to previous studies.[@CR9],[@CR13],[@CR24]--[@CR27] Outcome measures of complications after salvage APR varied widely in other studies, preventing adequate comparison. However, in the current study, surgical reinterventions were slightly more common (25.5%) than the range reported by others (12--20%).[@CR13],[@CR24]--[@CR26] In this study, 31.9% of patients experienced perineal complications, while others reported perineal complications in 22--50% of patients, regardless of use of muscle flap reconstruction.[@CR9],[@CR13],[@CR16],[@CR25],[@CR27] We could not identify a group prone to perineal complications based on time between radiotherapy and surgery or use of muscle flap reconstruction, possibly due to small numbers.

The 5-year OS in this study of 41.6% lies within the range of 23--69% reported by other authors. Survival of patients with persistent disease did not differ significantly from that of patients with recurrent disease, which is also in agreement with results published previously,[@CR10],[@CR11],[@CR14],[@CR15],[@CR17],[@CR19],[@CR28] although some studies did report poorer survival rates in patients with persistent compared with recurrent disease.[@CR10],[@CR16] This could be explained by more aggressive behavior of tumor cells in persistent disease or fast regrowth. However, other studies reported significantly worse survival in patients with recurrent disease, which could not be explained clearly.[@CR29],[@CR30]

We found that increased pathological tumor size, lymph node involvement, and positive resection margins adversely affected survival, which is in concordance with most other series (Appendix [1](#Sec14){ref-type="sec"}).[@CR9]--[@CR11],[@CR13]--[@CR15],[@CR17],[@CR24],[@CR25],[@CR28],[@CR30]--[@CR32] Although not identified on multivariable analysis in the present study, positive resection margin seems to remain the most common factor negatively affecting survival. These findings emphasize the importance of achieving negative resection margins, which can sometimes only be achieved by aggressive multivisceral resection or multidisciplinary treatment.

Recently, Hallemeier et al.[@CR30] reported a multidisciplinary approach, including reirradiation with or without concomitant chemotherapy and IORT, in a small group of patients with persistent or recurrent anal cancer. Only 21% developed recurrence within the reirradiated area. The 5-year OS was 23%, but they specifically treated patients with expected narrow or positive resection margins.[@CR30] In the present study, only two patients received IORT, and none received reirradiation prior to salvage surgery, because of the high-dose radiotherapy used as primary treatment. Wright et al.[@CR33] retrospectively analyzed 14 patients with locoregional recurrent anal SCC who underwent salvage surgery and IORT. Addition of IORT was not associated with locoregional control or survival benefit and did not compensate for positive surgical margins.[@CR33] Reirradiation and IORT could potentially decrease local recurrence rate, but this remains unclear.

Currently there is no role for standard adjuvant chemotherapy, however the combination of cisplatin and 5-fluorouracil (5-FU) is the gold standard in metastatic disease, with an overall response rate of 60%.[@CR34],[@CR35] Eng et al.[@CR36] showed a prolonged OS for multidisciplinary management with systemic chemotherapy and intervention compared with palliative chemotherapy only in patients with unresectable and metastatic anal SCC.[@CR36] In the present study, three patients received postoperative chemotherapy without additional intervention. Therefore, we could not clearly assess the effect on OS. Multidisciplinary treatment for unresectable and metastatic anal SCC can potentially lead to prolonged OS.

To our knowledge, this is the first study to present data on treatment of recurrent anal SCC after failed CRT for primary anal SCC and salvage APR for recurrent/persistent anal SCC. Alamri et al.[@CR27] and Correa et al.[@CR24] only reported survival for these patients. Some patients with local recurrence after salvage APR also had distant metastases or locoregional recurrence, and type of surgery was not protocolled as it is for the primary salvage APR. On the other hand, our results clearly show that recurrence after salvage APR has poor prognosis, regardless of the treatment. Palliative surgery may still be considered for some patients, especially those with pain. Cure, however, does not seem to be possible.

This study is limited by its retrospective nature and the small number of patients collected over a long time period. Patients with persistent or recurrent disease have different tumor biology, and mixing these cases could affect the outcomes of salvage APR. Advances in diagnostic imaging and treatment were made during the study period and likely contributed to heterogeneity in our study population and outcomes.

CONCLUSIONS {#Sec13}
===========

The results of the present study show that salvage APR for patients with SCC of the anal canal after failed CRT provides adequate long-term survival and local control. Prognostic factors for survival were advanced tumor stage, lymph node involvement, and positive resection margins. Patients with recurrent anal SCC after salvage APR had poor prognosis irrespective of performance of repeat salvage surgery, which never resulted in cure.

Appendix 1: Overview of Current Literature {#Sec14}
==========================================

Ref.Year of publicationNo. of patients5-Year OS (%)Prognostic factors for OS after salvage APRZelnick et al.[@CR20]1992924Not identified or not mentionedEllenhorn et al.[@CR11]19933844Nodal diseaseTumor fixed to lateral pelvic wallInvolvement of perirectal fatLongo et al.[@CR6]19943423--53StageMethod of treatmentPocard et al.[@CR37]19982133Not identified or not mentionedAllal et al.[@CR29]19992645Not identified or not mentionedSmith et al.[@CR18]20012233Not identified or not mentionedVan der Wal et al.[@CR19]20011747Not identified or not mentionedNilsson et al.[@CR16]20023552Persistent diseaseAkbari et al.[@CR10]20046233Tumor size \> 5 cmLocal extentNodal diseasePositive resection marginsGhouti et al.[@CR12]20053669Not identified or not mentionedFerenschild et al.[@CR38]20051830Not identified or not mentionedRenehan et al.[@CR9]20057340Positive resection marginsMullen et al.[@CR15]20063164Nodal disease\< 55 Gy radiotherapy doseStewart et al.[@CR31]20072224--48Tumor differentiationPositive resection marginsSchiller et al.[@CR17]20074039Tumor sizeSex (male)Mariani et al.[@CR14]20088357Age \> 55 yearsNodal diseaseT3--4 tumorLocal extentSunesen et al.[@CR25]20094961Positive resection marginsEeson et al.[@CR32]20115129Positive resection marginsCorrea et al.[@CR24]201211125Nodal diseasePositive resection marginPerineural and/or lymphovascular invasionLefevre et al.[@CR13]201210561T3--T4 statusPositive resection marginsMetastatic diseaseHallemeier et al.[@CR30]20143223Recurrent disease versus persistent diseasePositive resection marginsViable disease in resection specimenAlamri et al.[@CR27]20162778None identifiedPesi et al.[@CR26]20172037None publishedPresent study20174741Increased pathological tumor size (mm)--Nodal disease--Positive resection margins
